TrialNature communications2024

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Filipa Lynce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.